6 results about "H influenzae type b" patented technology

The present invention is inter alia directed to immunogenic compositions comprising: (a) a first hemagglutinin (HA) antigen or a first nucleic acid, suitably mRNA, encoding the first HA antigen wherein the first HA antigen is derived from a strain of Influenza virus; and (b) a second HA antigen or a second nucleic acid, suitably mRNA, encoding the second HA antigen wherein the second HA antigen is derived from a strain of Influenza virus, wherein (a) and (b) are different, and wherein the ratio of (a):(b) is comprised between 1.5:1 and 5:1. The present invention is also directed to vaccines and kits or kits-of-parts comprising such. Immunogenic compositions, vaccines and kits-of-parts provided herein are suitable for use as a medicament, in particular, for use in the treatment or prophylaxis of an infection with an Influenza virus, suitably an Influenza A and / or Influenza B.

Provided herein are nucleoside-modified ribonucleic acid molecules encoding a chimeric influenza virus hemagglutinin (HA) polypeptide that comprises a HA globular head domain and a HA stalk domain, wherein the HA stalk domain comprises an amino acid sequence of a HA stalk domain of an influenza B, the HA globular head domain comprises an amino acid sequence of a HA globular head domain of an influenza A, or the HA globular head domain comprises an amino acid sequence of a HA globular head domain of the influenza B, wherein one or more antigenic sites have been replaced with antigenic sites of an influenza A, and the nucleoside-modified RNA molecule comprises at least one pseudouridine. Also provided herein are methods of immunizing a subject against influenza virus disease and methods of preventing influenza virus symptoms in a subject using a composition described herein.

The present disclosure provides multivalent influenza vaccine compositions comprising at least three messenger RNAs (mRNA) encoding a combination of influenza A and influenza B hemagglutinin (HA) antigens, and methods of eliciting an immune response by administering the same, wherein the mRNA encoding the HA antigen of the influenza A virus is present in a different ratio (w / w) to the mRNA encoding the influenza B virus. In particular, the disclosure relates to mRNA encoding these antigens formulated into lipid nanoparticles (LNPs).

The present disclosure relates to the production of modified influenza B hemagglutinin (HA) proteins. More specifically, the disclosure relates to the production and increased production of influenza virus-like particles (VLPs) in plants, where the VLPs comprise modified influenza B HA proteins. The HA proteins can comprise an amino acid sequence that includes at least one substitution when compared to the corresponding wild-type amino acid sequence. Nucleic acids encoding the modified B HA proteins are further provided. Also provided are methods of producing influenza virus-like particles (VLPs) and methods of increasing influenza virus-like particle (VLP) production in a host or host cell.

The present invention provides, among other things, a novel and improved method for generating “mosaic” influenza antigenic polypeptides including hemagglutinin (HA) and neuraminidase (NA) polypeptides based on unique combination of epitope patterns that maximize exposure to epitopes present across multiple HA or NA sequences and therefore improved influenza strain coverage. In particular, the present invention provides engineered influenza B hemagglutinin (HA) polypeptides that are comprised of novel combinations of protective epitopes and antigenic regions from multiple influenza B viral strains. Such engineered HA polypeptides have improved properties over HA polypeptides developed through conventional approaches that rely on consensus alignments of viral sequences.

Provided herein are monoclonal antibodies or antigen-binding fragments thereof that bind to an influenza B hemagglutinin (HA) protein, pharmaceutical compositions comprising the antibodies, and methods of use. The antibodies can be used to inhibit or neutralize the activity of an influenza B virus, thereby providing a method of treating or preventing an influenza infection in a human. Also provided is the use of one or more antibodies that bind to the influenza B HA for preventing viral adsorption and / or entry into a host cell. The antibodies can be used prophylactically or therapeutically, and can be used alone or in combination with one or more other antiviral agents or vaccines.